Patients with HER2 gene amplification, normal left ventricular ejection fraction (LVEF), and resistant relapse after first- or second-line paclitaxel/carboplatin chemotherapy received paclitaxel ...

Paclitaxel (Taxol ®) has a broad activity spectrum and is clinically used, often in combination with carboplatin ... of adverse drug reactions after chemotherapy varies greatly among individuals ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

The results come from Part 1 of the study, comparing Jemperli (dostarlimab) with carboplatin-paclitaxel chemotherapy to placebo and chemo as a frontline treatment for advanced endometrial cancer ...

Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more pronounced pathologic ...

The approval is based on the RUBY trial, which showed that Jemperli (dostarlimab) given with carboplatin and paclitaxel chemotherapy achieved a 31% reduction in the risk of death compared to chemo ...

Mok and colleagues hypothesized that first-line therapy with the EGFR inhibitor gefitinib would be at least as efficacious as carboplatin–paclitaxel chemotherapy in former smokers and light ...

Thymic carcinoma, a rare cancer, is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy. Now, researchers ...